Abstract
The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.
| Original language | English |
|---|---|
| Pages (from-to) | 7-15 |
| Number of pages | 9 |
| Journal | Clinical Colorectal Cancer |
| Volume | 15 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Mar 1 2016 |
Fingerprint
Keywords
- Bevacizumab
- Colorectal cancer
- Efatutazone
- EGFR inhibitors
- Erlotinib
- Maintenance
- MGN1703
- Treatment duration
ASJC Scopus subject areas
- Oncology
- Gastroenterology
Cite this
Maintenance Therapy in Colorectal Cancer : Moving the Artillery Down while Keeping an Eye on the Enemy. / Aprile, Giuseppe; Giuliani, Francesco; Lutrino, Stefania Eufemia; Fontanella, Caterina; Bonotto, Marta; Rihawi, Karim; Fasola, Gianpiero.
In: Clinical Colorectal Cancer, Vol. 15, No. 1, 01.03.2016, p. 7-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Maintenance Therapy in Colorectal Cancer
T2 - Moving the Artillery Down while Keeping an Eye on the Enemy
AU - Aprile, Giuseppe
AU - Giuliani, Francesco
AU - Lutrino, Stefania Eufemia
AU - Fontanella, Caterina
AU - Bonotto, Marta
AU - Rihawi, Karim
AU - Fasola, Gianpiero
PY - 2016/3/1
Y1 - 2016/3/1
N2 - The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.
AB - The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance. Indeed, patients whose disease is controlled after induction chemotherapy may benefit from continuing a less intensive regimen in order to reinforce the results achieved with up-front treatment. In addition, the more favorable toxicity profile of maintenance approaches would ensure a better quality of life. After discussing the rationale and the difference of pursuing a maintenance strategy with chemotherapeutic and/or biologic agents, we present significant available data from the literature and comment on the current implications and future directions of maintenance therapy. The current roles of depotentiated treatment schedules, antiangiogenic compounds, epidermal growth factor receptor inhibitors, and novel targeted therapies are also reviewed. Finally, we address elements that may foster clinical and social debate on this topic, suggesting potential aspects that need to be further investigated.
KW - Bevacizumab
KW - Colorectal cancer
KW - Efatutazone
KW - EGFR inhibitors
KW - Erlotinib
KW - Maintenance
KW - MGN1703
KW - Treatment duration
UR - http://www.scopus.com/inward/record.url?scp=84960110381&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960110381&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2015.08.002
DO - 10.1016/j.clcc.2015.08.002
M3 - Article
AN - SCOPUS:84960110381
VL - 15
SP - 7
EP - 15
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
SN - 1533-0028
IS - 1
ER -